ArticlePolymers2022
The Treatment of Keloid Scars via Modulating Heterogeneous Gelatin-Structured Composite Microneedles to Control Transdermal Dual-Drug Release.
Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Hydrogel microneedles functioning in pathological surroundings: where soft materials overcome hard scars.Materials today. Bio · 2026Review
- Nanotechnologies for Skin Drug Delivery: Polymeric, Bio-Based, and Hybrid Nanocarriers with Clinical and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Traditional Chinese medicine ingredients integrated microneedles: A promising strategy for transdermal treatment.Asian journal of pharmaceutical sciences · 2026Review
- Research advances on protein-based microneedles for treatment of skin diseases: A review.Materials today. Bio · 2026Review
- Epithelial-mesenchymal transition in cutaneous fibrosis disease: from mechanisms to therapy.Frontiers in immunology · 2026Review
- A Novel Nude Mice Model for Studying the Pathogenesis of Keloid.Journal of cosmetic dermatology · 2025Article
- Multifunctional Hydrogel Microneedles (HMNs) in Drug Delivery and Diagnostics.Gels (Basel, Switzerland) · 2025Review
- Therapeutic Potential of Microneedle Assisted Drug Delivery for Wound Healing: Current State of the Art, Challenges, and Future Perspective.AAPS PharmSciTech · 2025Review
- Leveraging Microneedles for Raised Scar Management.Polymers · 2025Review
- Research Progress of Hydrogel Microneedles in Wound Management.ACS biomaterials science & engineering · 2024Review
- New challenges in scar therapy: the novel scar therapy strategies based on nanotechnology.Nanomedicine (London, England) · 2024Review
- Hydrogel Loaded with Components for Therapeutic Applications in Hypertrophic Scars and Keloids.International journal of nanomedicine · 2024Review
- Revisiting roles of mast cells and neural cells in keloid: exploring their connection to disease activity.Frontiers in immunology · 2024Article
- Exosome-mimetic vesicles derived from fibroblasts carrying matrine for wound healing.Burns & trauma · 2024Article
- Quercetin and Related Analogs as Therapeutics to Promote Tissue Repair.Bioengineering (Basel, Switzerland) · 2023Review
- A Review of Patents and Innovative Biopolymer-Based Hydrogels.Gels (Basel, Switzerland) · 2023Review
- Soluble Polymer Microneedles Loaded with Interferon Alpha 1b for Treatment of Hyperplastic Scar.Polymers · 2023Article
- A Sustainable Solution to Skin Diseases: Ecofriendly Transdermal Patches.Pharmaceutics · 2023Review
- The State of the Art of Natural Polymer Functionalized FeGels (Basel, Switzerland) · 2023Review
- Metallic elements combine with herbal compounds upload in microneedles to promote wound healing: a review.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Keloid scarring is an abnormal scar disease characterised by excessive proliferation of fibroblasts and over-deposition of collagen during wound healing. Although various treatments for keloid scars have been developed, preventive medicine is believed to be a promising strategy. The skin barrier limits the gentle topical administration of medicaments such as creams and hydrogel dressings, resulting in reduced therapeutic efficacy. In recent years, microneedles (MNs) have been regarded as an appreciable device for topical administration without inducing side effects, and they are painless and do not cause bleeding. In this study, an MN patch with controlled transdermal dual-drug release was developed to achieve combinatory treatment of keloid scars using a heterogeneous gelatin-structured composite MN. Gelatin hydrogel was used as a substrate to load gallic acid (GA) and quercetin-loaded amphiphilic gelatin nanoparticles to fabricate dual-drug heterogeneous composite MNs. The results of the insertion test and mechanical properties of the MNs showed that the heterogeneous composite MN patches could be self-pressed into the stratum corneum and control dual-drug release at different time periods. GA was released at an earlier stage to retard the proliferation of fibroblasts, and quercetin was released at a later stage as a strong antioxidant to erase the generation of reactive oxygen species. Furthermore, real-time quantitative polymerase chain reaction data indicated that the gene expression of fibroblasts (such as Col I and III) was downregulated in the dual-drug system. The above results demonstrate that using heterogeneous composite MNs with the combination of dual-drug pharmacology is beneficial for preventing keloid scar formation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.